Table 3: Program sensitivity according to demographic, screening, and tumor characteristics.

Screen-detected CRCInterval CRC ≤30 monthsCRC diagnosed >30 monthsProgram sensitivity*
(%) (%) (%)%

Gender
 Men65 (67.0)47 (63.5)62 (63.9)58.0
 Women32 (33.0)27 (36.5)35 (36.1)54.0
Age at diagnosis
 50–59 29 (33.3)13 (17.6)5 (5.2)69.0
 60–6945 (51.7)54 (73.0)32 (33.0)45.5
 ≥7023 (14.9)7 (9.5)60 (61.9)76.7
Screening
 First screening53 (54.6)26 (35.1)58 (59.8)67.1
 Successive screenings44 (45.4)48 (64.9)39 (40.2)47.8
Last screening round
 123 (23.7)11 (14.9)38 (39.2)67.6
 213 (13.4)14 (18.9)34 (35.1)48.1
 327 (27.8)20 (27.0)14 (14.4)57.4
 434 (35.1)29 (39.2) 11 (11.3)#54.0
Number of screens
 153 (54.6)26 (35.1)58 (59.8)67.1
 217 (17.5)27 (36.5)30 (30.9)38.6
 319 (19.6)16 (21.6)7 (7.2)54.3
 48 (8.2)5 (6.8)2 (2.1)61.5
Tumor site**
 Proximal23 (23.7)15 (25.0)28 (40.0)60.5
 Distal56 (57.7)20 (33.3)24 (34.3)73.7
 Rectum18 (18.6)25 (41.7)18 (25.7)41.9
Tumor stage**
 I39 (40.2)9 (14.8)14 (17.3)81.3
 II18 (18.6)17 (27.9)27 (33.3)51.4
 III30 (30.9)28 (45.9)27 (33.3)51.7
 IV10 (10.3)7 (11.5)13 (16.0)58.8

Only CRC detected in individuals with a negative result in their last screening were considered; *sensitivity expressed as the proportion of CRC diagnosed during the screening divided by all CRC diagnosed among screening participants up to 30 months; **variables with missing values; 26 CRC diagnosed after a negative gFOBT and 3 CRC diagnosed after a negative FIT; 9 CRC diagnosed after a negative gFOBT and 2 CRC diagnosed after a negative FIT.